ストックスクリーナーアプリを入手
337.61
1.90%
6.29
アフターアワーズ：
337.61
前日終値:
$331.32
開ける：
$331
24時間の取引高:
769.60K
Relative Volume:
2.19
時価総額：
$7.25B
収益：
-
当期純損益:
$-510.45M
株価収益率:
-17.55
EPS:
-19.24
ネットキャッシュフロー:
$-455.82M
1週間 パフォーマンス:
+55.02%
1か月 パフォーマンス:
+61.99%
6か月 パフォーマンス:
+46.89%
1年 パフォーマンス:
+129.84%
1日の値動き範囲:
$316.67
$337.63
1週間の範囲:
$213.71
$337.63
52週間の値動き範囲:
$133.99
$337.63
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
名前
Madrigal Pharmaceuticals Inc
セクター
電話
404-380-9263
住所
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-12-20 | 繰り返されました | Oppenheimer | Outperform |
| 2022-12-19 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-12-19 | 繰り返されました | Piper Sandler | Overweight |
| 2022-12-19 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-08-06 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 再開されました | Goldman | Buy |
| 2020-11-24 | 再開されました | Evercore ISI | Outperform |
| 2020-11-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-06-05 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-05-05 | 開始されました | Chardan Capital Markets | Buy |
| 2020-01-30 | 開始されました | Canaccord Genuity | Buy |
| 2020-01-09 | アップグレード | UBS | Neutral → Buy |
| 2019-11-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-25 | 開始されました | Stifel | Hold |
| 2019-06-10 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Outperform |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-12-12 | 開始されました | B. Riley FBR | Neutral |
| 2018-11-19 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 開始されました | Citigroup | Buy |
| 2018-08-06 | ダウングレード | Goldman | Buy → Neutral |
| 2018-06-28 | 開始されました | Raymond James | Mkt Perform |
すべてを表示
Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース
B. Riley Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
Check Out What Whales Are Doing With MDGL - Benzinga
Madrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 1-Year High on Analyst Upgrade - MarketBeat
Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations - Yahoo Finance
What is Leerink Partnrs' Forecast for MDGL FY2028 Earnings? - MarketBeat
Emerald Advisers LLC Has $5.79 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? - Benzinga
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion - Seeking Alpha
(MDGL) Long Term Investment Analysis - Stock Traders Daily
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH - Yahoo Finance
Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically - Simply Wall St
Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts - Yahoo Finance
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up - MSN
Madrigal Pharmaceuticals Announces Strong Q3 2024 Results and Strategic Advances - MSN
MDGL stock soars to 52-week high, reaching $299.99 By Investing.com - Investing.com South Africa
Madrigal Pharma Stock Soars Despite Novo Nordisk’s ‘Superior’ MASH Trial Results: Retail Bullish On Earnings Beat - MSN
Novo's Wegovy Isn't A 'Silver Bullet' For MASH. Madrigal Rockets. - Investor's Business Daily
Madrigal Pharmaceuticals stock jumps on MASH drug hopes - Yahoo Finance
Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $441.00 at UBS Group - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Earnings Results, Beats Estimates By $2.02 EPS - MarketBeat
MDGL stock soars to 52-week high, reaching $299.99 - Investing.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Sees Strong Trading Volume After Strong Earnings - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2024 Earnings Call Transcript - MSN
Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug - Yahoo Finance
Madrigal Pharmaceuticals Inc (MDGL) Q3 2024 Earnings Call Highlights: Strong Sales and ... - Yahoo Finance
Madrigal Pharmaceuticals Reports Strong Rezdiffra Launch - TipRanks
Madrigal Shatters Street Expectations With $62m In Q3 Rezdiffra Sales - Citeline
Madrigal stock jumps 13% after Rezdiffra Q3 sales beat estimates - MSN
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap UpShould You Buy? - MarketBeat
Madrigal Pharmaceuticals (MDGL) Shares Cross Above 200 DMA - Nasdaq
Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Madrigal: Q3 Earnings Snapshot - San Francisco Chronicle
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates - The Manila Times
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting® - The Manila Times
Cavalier Investments LLC Buys New Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals: Looking To Finally Establish A Position Around The Q3 Earnings - Seeking Alpha
Mirae Asset Global Investments Co. Ltd. Sells 5,915 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals Advances NASH Treatment with Full Enrollment of MAESTRO-NASH OUTCOMES Trial - MSN
Madrigal Pharmaceuticals' SWOT analysis: rezdiffra launch fuels stock's potential - Investing.com India
Madrigal Pharmaceuticals' SWOT analysis: rezdiffra launch fuels stock's potential By Investing.com - Investing.com South Africa
Madrigal: Why I'm Having Doubts On Bull Case Ahead Of Q3 Earnings (NASDAQ:MDGL) - Seeking Alpha
Madrigal Pharmaceuticals (MDGL) Set to Announce Earnings on Thursday - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $341.75 Average Price Target from Analysts - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) PT Lowered to $350.00 at Oppenheimer - MarketBeat
Where are the Opportunities in (MDGL) - Stock Traders Daily
Madrigal Pharmaceuticals (NASDAQ:MDGL) Earns Buy Rating from HC Wainwright - MarketBeat
Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug - Yahoo Finance
MDGLMadrigal Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Madrigal nears NASH treatment breakthrough with trial completion - Investing.com
Madrigal Pharmaceuticals Set to Reveal Q3 2024 Financial Results - MSN
Madrigal Pharmaceuticals Inc (MDGL) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):